COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,784 Articles (22,523 medRxiv, 8,261 bioRxiv)

Most recent first Previous |  Page 3030: Articles 30291-30300  | Next

Quantifying dynamics of SARS-CoV-2 transmission suggests that epidemic control and avoidance is feasible through instantaneous digital contact tracing
Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Bonsall, D. G., Fraser, C.
10.1101/2020.03.08.20032946 — Posted: 2020-03-12
The effectiveness of full and partial travel bans against COVID-19 spread in Australia for travellers from China.
Costantino, V., Heslop, D. J., MacIntyre, C. R.
10.1101/2020.03.09.20032045 — Posted: 2020-03-12
Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China
Wang, Y., Jiang, W., He, Q., Wang, C., Wang, B., Zhou, P., Dong, N., Tong, Q.
10.1101/2020.03.06.20032342 — Posted: 2020-03-12 Discussion: Onsite
Revealing the influence of national public health policies for the outbreak of the SARS-CoV-2 epidemic in Wuhan, China through status dynamic modeling
qiu, t., Xiao, H.
10.1101/2020.03.10.20032995 — Posted: 2020-03-12
Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2
Su, Y., Anderson, D., Young, B., Zhu, F., Linster, M., Kalimuddin, S., Low, J., Yan, Z., Jayakumar, J., Sun, L., Yan, G., Mendenhall, I., Leo, Y.-S., Lye, D., Wang, L.-F., Smith, G.
10.1101/2020.03.11.987222 — Posted: 2020-03-12 Discussion: Onsite
Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2
Xiong, R., Zhang, L., Li, S., Sun, Y., Ding, M., Wang, Y., Zhao, Y., Wu, Y., Shang, W., Jiang, X., Shan, J., Shen, Z., Tong, Y., Xu, L., Chen, Y., Liu, Y., Zou, G., Lavillete, D., Zhao, Z., Wang, R., Zhu, L., Xiao, G., Lan, K., Li, H., Xu, K.
10.1101/2020.03.11.983056 — Posted: 2020-03-12 Discussion: Onsite
Rigidity, normal modes and flexible motion of a SARS-CoV-2 (COVID-19) protease structure.
Wells, S. A.
10.1101/2020.03.10.986190 — Posted: 2020-03-12 Discussion: Onsite
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Yang, H., Hong, L., Wu, N., Yuan, E., Cheng, L., Lei, Y., Shu, H., Feng, X., Jiang, Z., Chi, Y., Guo, X., Cui, L., Xiao, L., Li, Z., Yang, C., Miao, Z., Tang, H., Chen, L., Zeng, H., Zhao, D., Zhu, F., Shen, X., Zeng, J.
10.1101/2020.03.11.986836 — Posted: 2020-03-12
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., Fukushi, S.
10.1101/2020.03.11.987016 — Posted: 2020-03-12 Discussion: Onsite
A human monoclonal 1 antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., Bosch, B.-J.
10.1101/2020.03.11.987958 — Posted: 2020-03-12 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).